University of Nevada, Reno

About: University of Nevada, Reno is a education organization based out in Reno, Nevada, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 13561 authors who have published 28217 publications receiving 882002 citations. The organization is also known as: University of Nevada & Nevada State University.

Cloud Droplet Growth by Collection

Abstract: Calculations of cloud droplet growth over the radius range from 4 to 200 μ for collection kernels representing hydrodynamic capture, electric field capture, and geometric sweep-out show that the rate of droplet growth is proportional to the magnitude of the kernel, and the pattern of growth depends upon a derivative of the kernel with respect to droplet size. Below 60 μ a large kernel derivative causes the distribution to spread. Above 6O μ the derivative of each kernel decreases to a common value that causes water to accumulate on large drops. This leads to a self-preserving distribution, similar to Golovin's, asymptotic solution, in about 5 min when the liquid water content is 1 gm m−3. The stochastic model produces a growth rate nearly equal to the continuous model but transfers much more water to larger drops.

Neural adjustments to image blur.

Abstract: Blur is an intrinsic feature of retina images that varies widely across images and observers, yet the world still typically appears 'in focus'. Here we examine the putative role of neural adaptation1 in the human perception of image focus by measuring how blur judgments depended on the state of adaptation. Exposure to unfocused images has previously been shown to influence acuity and contrast sensitivity and here we show that adaptation can also profoundly affect the actual perception of image focus.

Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial

Abstract: BACKGROUND Increased mammographic density reduces the sensitivity of screening mammography, is associated with increased breast cancer risk, and may be hormone related. We assessed the effect of estrogen-plus-progestin therapy on mammographic density. METHODS In a racially and ethnically diverse ancillary study of the Women's Health Initiative, we examined data from 413 postmenopausal women who had been randomly assigned to receive daily combined conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (i.e., progestin; 2.5 mg) (n = 202) or daily placebo (n = 211). We assessed the effect of estrogen plus progestin on measured mammographic percent density and abnormal findings over a 1-year and 2-year period. All tests of statistical significance were two-sided and were based on F tests or t tests from mixed-effects models. RESULTS Mean mammographic percent density increased by 6.0% at year 1, compared with baseline, in the estrogen-plus-progestin group but decreased by 0.9% in the placebo group (difference = 6.9%, 95% confidence interval [CI] = 5.3% to 8.5%; P < .001). The mean changes in mammographic density persisted but were attenuated slightly after 2 years, with an absolute increase of 4.9% in the estrogen-plus-progestin group and a decrease of 0.8% in the placebo group (difference = 5.7%, 95% CI = 4.3% to 7.3%; P < .001). These effects were consistent across racial/ethnic groups but were higher among women aged 70-79 years in the estrogen-plus-progestin group (mean increase at year 1 = 11.6%) than in the placebo group (mean decrease at year 1 = 0.1%) (difference of the means = 11.7%, 95% CI = 8.2% to 15.4%; P < .001, comparing across age groups). At year 1, women who were adherent to treatment in the estrogen-plus-progestin group had a mean increase in density of 7.7% (95% CI = 5.9% to 9.5%), and women in the placebo group had a mean decrease in density of 1.1% (95% CI = 0.3% to 1.9%). Use of estrogen plus progestin was associated with an increased risk of having an abnormal mammogram at year 1 (relative risk = 3.9, 95% CI = 1.5 to 10.2; P = .003), compared with placebo, that was not explained by an increase in density. CONCLUSIONS Use of up to 2 years of estrogen plus progestin was associated with increases in mammographic density.